T3D Therapeutics announced it has been awarded a competitive $50,000 Company Inception Loan (CIL) from the North Carolina Biotechnology Center. The CIL Program is designed to help bridge the early-stage funding gap that many North Carolina biotechnology companies...

T3D Therapeutics announced that is has successfully completed its seed round financing. The financing round was over-subscribed.

DARA BioSciences, Inc. (NASDAQ: DARA), a specialty pharmaceutical company focused on oncology supportive care products, announced today that it has granted T3D Therapeutics, Inc. the exclusive worldwide rights to develop and commercialize DB959. DB959 is an oral,...

Bruce K. Burnett, PhD, RAC (US, EU) is Director of Regulatory Affairs at Duke Translational Medicine Institute. Dr. Burnett received his undergraduate degree in organic chemistry from the University of California, San Diego and his PhD in organic...

T3D Therapeutics will introduce T3D-959, a transformational new drug therapy in development for the treatment of Alzheimer's disease. Read More

T3D Therapeutics announced the creation of its Advisory Board with the addition of three members who are experts in the field of Alzheimer’s disease and other central nervous system disorders; Lawrence Friedhoff, M.D., Ph.D., FACP, Warren Strittmatter, M.D. and Joseph...

T3D Therapeutics announced the appointment of Charles Lineberry, Ph.D. and Barry Buzogany, Esq. to its Board of Directors. Dr. Lineberry, founder and president of Lineberry Research Associates, has a Ph.D. in physiological psychology, NIH post-doctoral training in...